Efficacy Of Etanercept Research Articles

Randomised, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept in patients with erosive inflammatory hand osteoarthritis

Randomised, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept in patients with erosive inflammatory hand osteoarthritis

Single nucleotide polymorphisms of ABCB1 gene and response to etanercept treatment in patients with ankylosing spondylitis in a Chinese Han population.

Background:Etanercept was highly recommended for patients with ankylosing spondylitis (AS), as its efficacy has been confirmed in AS, while genetic polymorphisms, by affecting drug metabolism or drug receptor, lead to interindividual variability in drug disposition and efficacy. Therefore, this study aims to investigate whether ABCB1 gene polymorphisms can predict therapeutic response to etanercept in patients with AS.Methods:A total of 185 patients with AS in our hospital were recruited into our study from December 2012 to May 2015. The frequency distributions of genotype and allele of rs2032582, rs1128503, and rs1045642 were detected by polymerase chain reaction (PCR) and electrophoresis verification enzyme products method. AS patients received etanercept treatment for 12 weeks, followed by this would be evaluated by the bath AS disease activity index (BASDAI) score improvement and the assessment of spondyloArthritis international society 20/50/70 (ASAS20/50/70) score improvements to explore the relationship between genotype of ABCB1 gene polymorphisms and therapeutic response to etanercept in patients with AS.Results:After 12 weeks, the BASDAI score mean improvement value of rs2032582 A/A genotype was 2.87 ± 0.52. The ratios of patients with rs2032582 A/A genotype reaching the BASDAI50 and ASAS20 evaluation criteria were 64.29% and 92.86%, respectively. The results indicated that efficacy of etanercept was promoted in rs2032582 A/A genotype. The BASDAI score mean improvement value of rs1128503 C/C genotype was 2.79 ± 0.54 after 12 weeks. The ratios of patients with rs1128503 C/C genotype reaching the BASDAI50 and ASAS20 evaluation criteria were 66.67% and 93.94%, respectively. The results indicated that efficacy of etanercept was promoted in rs1128503 C/C genotype. However, no significant associations were observed between rs1045642 and therapeutic response to etanercept in AS patients.Conclusion:ABCB1 gene rs2032582 and rs1128503 polymorphisms may be associated with the efficacy of etanercept in AS patients. ABCB1 gene polymorphisms can act as biological indicators of etanercept efficacy.

The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept

To discover how NLRP3 and TNFRSF1A polymorphisms affect the efficacy of traditional medicine and etanercept for ankylosing spondylitis (AS) patients. Single nucleotide polymorphism (SNP) and haplotype analyses were conducted based on determined NLRP3 and TNFRSF1A among AS patients. We subsequently analyzed the relationship between relevant clinical indexes and polymorphisms of NLRP3 and TNFRSF1A. The 4 SNP loci on NLRP3 and 3 SNP loci on TNFRSF1A showed significant linkage disequilibrium, respectively. The T allele of NLRP3 rs4612666 and the T allele of TFRSF1A rs4149570 are both associated with AS (P<.05). The T-A-C-T haplotype of NLRP3 as well as the G-C-C, T-C-C, T-C-T, and T-T-T haplotypes of TFRSF1A are associated with AS (P<.05). The morning stiffness time, BASDAI scoring, and ESR of patients receiving etanercept were significantly higher than those receiving traditional medicine. T allele of NLRP3 rs4612666 had a significantly greater negative impact on the ASAS20 improvement than C allele. Whereas the A allele of NLRP3 rs3806268 had a significantly greater positive impact on the ASAS20 improvement than G allele. There is no significant association between SNP and efficacy of traditional medicine in the treatment of AS. NLRP3 and TFRSF1A (rs4149570) are associated with AS susceptibility. There is a significant association between NLRP3 polymorphisms and treatment of etanercept.

DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS.

We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS). We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome. Secondary outcomes included 50 percent increase in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) used for evaluating efficacy, as well as the BASDAI/Bath Ankylosing Spondylitis Functional Index (BASFI) scores and adverse events. ASAS 20 indicated that the efficacy of etanercept did not differ amongst dosing regimens (25 mg twice-weekly versus 50 mg once-weekly: relative risk [RR], 2.18, 95 percent confidence interval [CI], 1.78-2.67 versus RR, 2.00, 95 percent CI, 1.70-2.37). The ASAS 20 reported subgroup differences among treatment durations of less than 12 weeks (RR, 2.70; 95 percent CI, 2.09-3.49); 12 weeks (RR, 1.74; 95 percent CI, 1.37-2.22); and more than 12 weeks (RR, 2.56; 95 percent CI, 1.88-3.48). Other outcomes included BASDAI, BASDAI 50, and BASFI. Drug safety differed according to the treatment regimen and duration. Our meta-analysis found that there was no significant efficacy difference between 50 mg once-weekly and 25 mg twice-weekly dosing for the treatment of AS, and a dosing duration of less than 12 weeks was more effective for treating AS patients.

Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis

The TNF inhibitors etanercept (ETA) and adalimumab (ADA) are approved for treating patients older than 2years with polyarticular juvenile idiopathic arthritis (JIA). Because long-term experience of treating children younger than 4years is limited, we evaluated the efficacy and safety of ETA or ADA in patients aged 2-4years. This prospective, long-term, observational registry study documented baseline demographics, clinical characteristics, disease activity parameters, and safety of patients treated with ETA or ADA. Efficacy was determined using the JADAS-10, the JADAS criteria for minimal disease activity (MDA) and remission, and the PedACR response criteria after 3, 6, 12, 18, and 24months. Between January 2001 and March 2015, 85 patients with polyarticular JIA aged 2-4years started anti-TNF-α treatment. Seventy-four (54 girls) patients were treated with ETA and 11 (7 girls) with ADA. After 6/12/24months of treatment, JADAS-MDA was reached by 55/58/58% of ETA patients and 50/71/66% of ADA patients. Furthermore, JADAS-Remission was achieved by 35/44/50% of ETA patients and 16/28/66% of ADA patients. PedACR 50/70/90 response was achieved by 64/54/41% of ETA patients and 56/33/22% of ADA patients at the last treatment observation. Discontinuation because of remission or inefficacy was recorded in 24 (29%) and 28 (33%) patients, respectively. Seventy-nine adverse events and four serious adverse events were reported. Administration of ETA and ADA in JIA patients younger than 4years was efficacious, well tolerated, and safe. Patients younger than 4years may show marked improvement following anti-TNF-alpha therapy.

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factors in patients with RA treated with etanercept. Metabolic analytes were measured at baseline, week 12, and week 24 in patients enrolled in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in moderately active RA. Patients received either placebo or etanercept 50 mg every week (QW) for 12 weeks, after which all patients received etanercept 50 mg QW through week 24. Levels of metabolic analytes were assessed in all patients, including patients with diabetes and hyperlipidemia, and described descriptively. A total of 210 patients were randomized, 104 to placebo and 106 to etanercept. There were no significant changes in metabolic risk factors from baseline to week 12 or 24 in all patients. Levels of metabolic analytes were similar in patients with diabetes and hyperlipidemia, with some exceptions; fasting glucose and fasting insulin decreased through week 12, and hemoglobin A1C decreased slightly through week 24 in patients with diabetes. Treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA.

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study.

Aim To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.Methods Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 – 24.99 kg/m2; overweight, BMI 25 – 29.99 kg/m2; obese, BMI ≥30 kg/m2).Results The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients.Conclusion Obesity has a negative effect on the efficacy of etanercept in psoriasis.

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry

ObjectiveIn a real-life setting, to analyse retrospectively the effects of different methotrexate regimens on etanercept efficacy during the first year of treatment for rheumatoid arthritis (RA).MethodsDemographic characteristics, clinical parameters and treatment data from patients with RA receiving the first-line biological disease-modifying antirheumatic drug, etanercept, as monotherapy or in combination with methotrexate were analysed at baseline and after 6 and 12 months. The study population was stratified into three groups according to the level of concomitant methotrexate therapy: no methotrexate, low-dose methotrexate (≤ 10 mg/week) or high-dose methotrexate (>10 mg/week).ResultsClinical response at 6 and 12 months and clinical outcome at 12 months were significantly better in patients concomitantly treated with high-dose methotrexate. Furthermore, this regimen was associated with the lowest discontinuation rate, suggesting a favourable safety profile.ConclusionThese data confirm, in a real-life setting, the importance of methotrexate as a combination therapy with etanercept and suggest that the minimal effective dose of methotrexate is >10 mg/week.

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50mg twice weekly followed by etanercept 25mg twice weekly, the combination of etanercept 25mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.

BackgroundEtanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis.MethodsSixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24.ResultsThe proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients.ConclusionIn Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study.Trial registrationThis study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065.

A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate.

The objective of the study was to evaluate the efficacy and safety of etanercept (Anbainuo) treatment in Chinese moderate to severe rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR); 600 patients (360 in phase III-1 and 240 in phase III-2) poorly responding to MTX were enrolled in the study and randomized at a ratio of 2:1 into an Anbainuo treatment or control group. The study was designed as a 12-week double-blind, placebo-controlled period followed by a 12-week open-label study. The primary endpoint was the ACR20 response rate at week 12. Secondary endpoints included the ACR50, ACR70, ACR-N, and safety. At week 12, ACR20 response was observed in 60.9% of the Anbainuo group-significantly higher than that of the control group (20.6%). At week 24, the ACR20 response in the Anbainuo group increased to 70.2%; there was no significant difference compared with that of the control group (61.8%, P > 0.05). At week 12, the ACR50 and ACR70 responses of the Anbainuo group increased to 25.6 and 6.8%, compared to 4 and 1% in the control group (P < 0.001, P = 0.002). The ACR-N was 2.85 ± 6.73 vs. -3.24 ± 8.78% in the control group (P < 0.001). During the first 12weeks of treatment, 66 adverse events (AE) were reported in the Anbainuo group (15.6%) and 21 AEs (10.5%) occurred in the control group, whereby the rate of the Anbainuo group was slightly higher than the control group (P = 0.042). Severe adverse events (SAEs) occurred in the Anbainuo group (1.3%) and one (SAE) occurred in the control group (0.5%) (P = 0.19). Anbainuo displays a rapid onset of efficacy as well as good tolerance and safety in MTX-IR patients having moderate to severe RA.

Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis

Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage

ObjectiveTo evaluate the impact of methotrexate (MTX) dosage on clinical, functional and quality of life outcomes in patients with rheumatoid arthritis (RA) from two previous etanercept (ETN) trials after 24...

Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.

Despite the demonstrated efficacy of etanercept for the treatment of ankylosing spondylitis (AS), sulfasalazine is often prescribed, especially in countries with limited access to biologic agents. The objective of this subset analysis of the ASCEND trial was to compare the efficacy of etanercept and sulfasalazine in treating patients with AS from Asia, Eastern/Central Europe, and Latin America. A total of 287 patients, 190 receiving etanercept 50 mg once weekly and 97 receiving sulfasalazine 3 g daily, from eight countries were included in this subset analysis. Differences in disease activity and patient-reported outcomes assessing health-related quality-of-life (HRQoL) parameters in response to treatment were analyzed using the Cochran-Mantel-Haenszel test for categorical efficacy endpoints and analysis of covariance model for continuous variables. At week 16, a significantly greater proportion of patients receiving etanercept achieved ASAS20 (79.0 %) compared with patients receiving sulfasalazine (61.9 %; p = 0.002). At week 16, treatment with etanercept also resulted in significantly better responses than sulfasalazine for ASAS40 (64.7 vs. 35.1 %; p < 0.001), ASAS5/6 (48.1 vs. 26.3 %; p < 0.001), proportion of patients achieving 50 % response in Bath AS Disease Activity Index (65.8 vs. 42.3 %; p < 0.001), partial remission (35.3 vs. 17.5 %; p = 0.002), and all HRQoL parameters. Both treatments were well tolerated. Etanercept was significantly more effective than sulfasalazine in the treatment of patients with AS from Asia, Central/Eastern Europe, and Latin America.

Etanercept for the treatment of non-radiographic axial spondyloarthritis

ABSTRACTPresently, tumor necrosis factor α antagonist therapy is the only effective alternative treatment to nonsteroidal anti-inflammatory drugs for the entire spectrum of axial spondyloarthritis, including non-radiographic and radiographic (=ankylosing spondylitis) forms. Recently, etanercept has been approved by the European Medicines Agency for the treatment of non-radiographic axial spondyloarthritis, increasing the number of available treatment options for this indication. The latest data on etanercept concerning clinical efficacy and safety in short-term and long-term treatment of patients with non-radiographic axial spondyloarthritis who do not respond to the first-line therapy with non-steroidal anti-inflammatory drugs suggests good efficacy and safety profiles similar to that observed previously in ankylosing spondylitis. This article reviews recent data on the efficacy and safety of etanercept and is focused on the treatment of non-radiographic axial spondyloarthritis. This article will also discuss the role of etanercept in the context of current and developing treatment options.

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.

AimThe relationship between tumour necrosis factor‐alpha (TNF‐α) and drug survival had not been studied in juvenile idiopathic arthritis (JIA), and there were no laboratory tests to predict the long‐term efficacy of biological drugs for JIA. We studied whether serum levels of TNF‐α, free or bound to etanercept, could predict long‐term efficacy of etanercept in children with JIA.MethodsWe included 41 biologic‐naïve patients with JIA who started treatment with etanercept at Skåne University Hospital between 1999 and 2010. Serum taken at the start of treatment and at the six‐week follow‐up were analysed for TNF‐α and the long‐term efficacy of etanercept was assessed using the drug survival time.ResultsLevels of TNF‐α increased significantly at the six‐week follow‐up, and this was almost exclusively comprised of TNF‐α in complex with etanercept. The increase in TNF‐α showed a dose‐dependent correlation to long‐term drug survival (p < 0.01).ConclusionIncreasing levels of circulating TNF‐α at treatment initiation predicted long‐term efficacy of etanercept in children with JIA, which may have been due to different pathophysiological mechanisms of inflammation. Our result may provide a helpful clinical tool, as high levels of circulating TNF‐α/etanercept complexes could be used as a marker for the long‐term efficacy of etanercept.

Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations

Background : At present, it is urgent to find ways to overcome the inefficiency of and intolerance to the methotrexate therapy in patients with juvenile idiopathic arthritis (JIA). A promising method is the use of TNF-alpha inhibitors as monotherapy. Objective : Our aim was to evaluate the efficacy and safety of etanercept monotherapy and treatment with etanercept and methotrexate in patients with JIA without systemic manifestations. Methods : Observational study with retrospective assessment of the treatment of patients who received etanercept — the treatment group (n = 55) and the combination of etanercept and methotrexate — the control group (n = 136). The efficacy was evaluated for 3 years using the pediatric criteria of the American College of Rheumatology (ACR), remission criteria by C. Wallace and index JADAS71. Results: Total amount of patients with JIA without systemic manifestations under study is 191. As early as 1 month after the first etanercept injection, clinical and laboratory parameters of disease activity significantly decreased in 83 and 77% and functional ability of joints improved in 87 and 74% of patients treated with TNF- inhibitor and its combination with methotrexate. After 6 months, the improvement according to the ACR pediatric criteria 30/50/70 was recorded in 98/98/96 and 96/95/86%; inactive stage of the disease/remission was recorded in 44 and 24% of patients who received etanercept and etanercept + methotrexate. After 1 year, the improvement was recorded in 100 and 100/98/93% of patients in the treatment group and the control group and inactive stage of the disease/remission — in 65 and 43% of patients. In the course of etanercept + methotrexate therapy, infectious adverse events were more common. 12.7 and 7.3% of patients treated with etanercept and methotrexate discontinued their participation in the study during the first 6 months and 18 and 10% — during the first year. 8.4% of patients treated with the combination of etanercept and methotrexate discontinued their participation in the study during the second year. Conclusion: Etanercept monotherapy is effective on a par with the combination therapy, but it has a higher safety profile and a lower therapy «survival».

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

There are no systemic therapies approved in the United States to treat pediatric psoriasis. We sought to evaluate long-term safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis. This 5-year, open-label extension study enrolled patients aged 4 to 17 years who had participated in a 48-week parent study. End points included occurrence of adverse events (AEs) and serious AEs including infections, and rates of 75% and 90% improvement in Psoriasis Area and Severity Index score and clear/almost clear on static physician global assessment. Of 182 patients enrolled, 181 received etanercept and 69 completed 264 weeks. Through week 264, 161 (89.0%) patients reported an AE, most commonly upper respiratory tract infection (37.6%), nasopharyngitis (26.0%), and headache (21.5%). Seven patients reported 8 serious AEs; only 1 (cellulitis) was considered treatment-related. No cases of opportunistic infections or malignancy were reported. Rates of 75% improvement in Psoriasis Area and Severity Index score (∼ 60%-70%) and 90% improvement in Psoriasis Area and Severity Index score (∼ 30%-40%) and static physician global assessment status clear/almost clear (∼ 40%-50%) were maintained through week 264. The number of patients remaining on study at week 264 was small. Etanercept in pediatric patients was generally well tolerated and efficacy was maintained in those who remained in the study for up to 264 weeks.

A study on efficacy and safety of etanercept in patients with rheumatoid arthritis

Aim and objective: To assess the efficacy of Etanercept and also to evaluate the safety profile of Etanercept in patients with Rheumatoid arthritis. The main objectives of the study are to evaluate the drug safety and efficacy among the Rheumatoid arthritis patients. And to monitor the ADRs observed in Rheumatoid arthritis patients with Etanercept. Materials and Methods: Study was carried out in a 300 bedded tertiary care hospital. The department selected for the study was orthopaedics. This method involves prospective observational analysis of Efficacy and safety of Etanercept in patients with Rheumatoid arthritis. The study was carried out by the collection and documentation of general information of the patient including personal history, past medical history, past medication history, lab investigations and treatment pain will be analysed by using visual analog scale(vas). ADR’s were assessed by using Naranjo adverse drug reaction probability scale. The whole procedure was carried out in Rheumatoid arthritis patients who received Etanercept without any alteration in therapy. Result and Discussion: This study on sample size of 35 was carried out to assess the short term safety and efficacy of Etanercept. Moreland et al compared placebo, ETN 10 mg twice weekly (ETN20), and ETN 25 mg twice weekly (ETN50) in patients with long-standing RA and an inadequate response to DMARDs. Although both treatment arms were significantly better than placebo, as measured by American College of Rheumatology. The study conducted by Elizabeth Mary Curtis et al., shows that Etanercept is a safe and well-tolerated treatment for RA, And another study conducted by Boulos Haraoui et al, study shows that Etanercept is both safe and effective to use in RA. Etanercept has been shown not only to reduce disease activity but also to limit progression of joint damage in early and late disease which are similar to our study. Conclusion: This study concludes incidence of rate of patients in the age group of 50 – 59 years were mostly affected by Rheumatiod arthritis compared to other age groups. The male patients were found to be affected more with rheumatoid arthritis than female patients. The study made use of 25mg Eternacept for the above obtained results. This could also be carried out using 50mg Eternacept and evaluated on the same. There was a decrease in pain VAS scale confirming the efficacy and safety of Etanercept. In the future, this study could be further extended to a combination therapy over longer duration of time for better results.

Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study

Objectives: To investigate the efficacy and safety of etanercept (ETN) in patients with rheumatoid arthritis (RA) with moderate disease activity and the possibility to discontinue ETN after achieving remission.Methods: Multicenter, randomized, and open-label study was conducted in Japan and Korea. RA patients (disease duration <5 years) with moderate disease activity despite methotrexate (MTX) treatment were allocated to either MTX or ETN + MTX (Period 1) for 12 months. Patients who achieved sustained remission defined as DAS28 < 2.6 at both 6 and 12 months in the ETN + MTX group, were randomized to either continue or discontinue ETN for 12 months (Period 2).Results: A total of 222 patients were enrolled in Period 1 and clinical remission was achieved in 106/157 (67.5%) and 5/28 (17.9%) patients in the ETN + MTX and MTX groups, respectively. In Period 2, sixty-seven patients were randomized and finally 28/32 (87.5%) and 15/28 (53.6%) patients who continued or discontinued ETN maintained clinical remission. Baseline disease activity and the presence of comorbid diseases influenced the maintenance of remission after ETN discontinuation.Conclusions: ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year.

Safety and Efficacy of Etanercept in a HCV/HBV Patient Affected by Psoriasis

Safety and Efficacy of Etanercept in a HCV/HBV Patient Affected by Psoriasis